Bristol Myers Squibb is shedding two clinical programs, one from its 2023 Mirati buyout and another from a partnership with U ...

BMS has won the $500bn-total insured value (TIV) Alliant Property Insurance Program (APIP) account from Howden, this ...

Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare ...

During BMS’ earnings call Thursday, CEO Chris Boerner, Ph.D., described Cobenfy as “delivering steady growth.” But the first-in-class drug still has a long way to go to fulfill its promise as a ...

DISP-10 is a novel tumor-specific virus and CAR T combination designed to overcome key challenges of applying CAR T therapy to solid tumors DISP-10 has broad potential to target all solid tumors of ...

Revenue Mix -- Approximately 55% of Q3 2025 revenue came from services (automotive OEMs, AI-enhanced battery material ...

Q3 2025 Earnings Call Transcript November 3, 2025 BioNTech SE misses on earnings expectations. Reported EPS is $-0.14 EPS, ...

CD19 chimeric antigen receptor T-cell therapy improved lung function and skin thickness in patients with severe refractory ...

Discovery & Preclinical Development segment ("D&PD", (12.3)%) still sees soft demand;Just - Evotec Biologics ("JEB"; +11.3%) above-expectation; further accelerating growth on non-Sandoz / non-DOD ...

Bristol Myers Squibb showcases new long-term and real-world data from cardiovascular portfolio at the AHA scientific sessions 2025: Princeton, New Jersey Wednesday, November 5, 20 ...

Following the CEC certification of the PowerPod single-phase all-in-one energy storage system, the entire WHES residential ...